Press Releases Choose Year All Items 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 Search Press Releases Found 265 Results March 9, 2026 Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference January 12, 2026 Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications December 3, 2025 Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology November 13, 2025 Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates November 7, 2025 Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025 November 4, 2025 Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer November 4, 2025 Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants October 7, 2025 Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01 September 16, 2025 Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement September 10, 2025 Relmada Issues Mid-Year CEO Letter to Shareholders 123456...»
